Palisade Bio Inc. Stock
Price
Target price
-
-
-
-
-
?21.22
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Palisade Bio Inc. Stock
Currently there is a rather positive sentiment for Palisade Bio Inc. with 5 Buy predictions and 1 Sell predictions.
Based on the current price of 0.34 € the target price of 21 € shows a potential of 6054.75% for Palisade Bio Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Palisade Bio Inc. stock. Criterium "Company culture" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Palisade Bio Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Palisade Bio Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Palisade Bio Inc. | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | -0.600% | 0.345% | -14.176% | -67.596% | 7.391% | -36.272% | -91.896% |
| Pacira Pharmaceuticals | 0.000% | -6.364% | 0.980% | 16.384% | -4.630% | -43.094% | -56.723% |
| Twist Bioscience Corp | 7.890% | 4.946% | 5.514% | -36.195% | 5.135% | 21.772% | -74.088% |
Comments
Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Clear Str Llc to a "strong-buy" rating.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat
Palisade Bio (NASDAQ:PALI) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $25.00 price target on the stock.
Show more
Ratings data for PALI provided by MarketBeat